Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,823 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,089 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06993116 | A Phase I Study of SHR-4712 in Patients With Advanced Solid Tumors | active not recruiting | Phase 1 | 15 | Guangdong Hengrui Pharmaceutical Co., LtdINDUSTRY | 1 | Jan 28, 2026 | clinicaltrials |
| NCT07151040 | Phase 1/2 Study to Evaluate TH9619 in the Treatment of Advanced Solid Tumors(ODIN) | recruiting | Phase 1 / Phase 2 | 43 | One-carbon Therapeutics ABINDUSTRY | 3 | Jan 28, 2026 |
| NCT07371663 | An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 266 | Beijing Tide Pharmaceutical Co., LtdINDUSTRY | 1 | Jan 28, 2026 | clinicaltrials |
| NCT05867420 | A Study of ASKG915 in Patients With Selected Advanced Solid Tumors. | recruiting | Phase 1 / Phase 2 | 594 | AskGene Pharma, Inc.INDUSTRY | 2 | Jan 27, 2026 | clinicaltrials |
| NCT05071209 | Elimusertib for the Treatment of Relapsed or Refractory Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 31 | National Cancer Institute (NCI)NIH | 2 | Jan 23, 2026 | clinicaltrials |
| NCT07348211 | First in Human Study of SIM0610 in Solid Tumors(SIM0610-101) | recruiting | Phase 1 | 260 | Jiangsu Simcere Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jan 23, 2026 | clinicaltrials |
| NCT07363369 | Exploratory Clinical Study of FAP mRNA Vaccine in Patients With Advanced Malignant Solid Tumors | not yet recruiting | Phase 1 | 10 | West China HospitalOTHER | 0 | Jan 23, 2026 | clinicaltrials |
| NCT07093970 | A Study of MRG006A in the Treatment of Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 343 | Lepu Biopharma Co., Ltd.INDUSTRY | 1 | Jan 22, 2026 | clinicaltrials |
| NCT07358806 | Study to Assess the Effect of OCT-598 in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 51 | Oscotec Inc.INDUSTRY | 1 | Jan 22, 2026 | clinicaltrials |
| NCT07358884 | First in Human Study of QLS5316 in Solid Tumors | not yet recruiting | Phase 1 | 300 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 0 | Jan 22, 2026 | clinicaltrials |
| NCT06503783 | A Study of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Negative Breast Cancer and Other Solid Tumors | recruiting | Phase 1 | 20 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jan 21, 2026 | clinicaltrials |
| NCT06609187 | A Study of GNC-077 in Patients With Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors | recruiting | Phase 1 | 20 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jan 21, 2026 | clinicaltrials |
| NCT06612840 | A Study of GNC-077 in Patients With Locally Advanced or Metastatic Non-small-cell Lung Cancer and Other Solid Tumors | recruiting | Phase 1 | 20 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jan 21, 2026 | clinicaltrials |
| NCT06959615 | A Phase I/IIa Study of JAB-23E73 in Patients With Advanced Solid Tumors Harboring KRAS Gene Alteration | recruiting | Phase 1 / Phase 2 | 334 | Jacobio Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Jan 20, 2026 | clinicaltrials |
| NCT07351903 | A Single-arm, Open-label Study of GK01 in Combination With or Without Chemotherapy for the Adjuvant Treatment of Solid Tumors(GUARDIAN-02) | recruiting | Phase 1 | 15 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jan 20, 2026 | clinicaltrials |
| NCT06302426 | Trial of INI-4001 in Patients With Advanced Solid Tumours | recruiting | Phase 1 | 50 | Inimmune CorporationINDUSTRY | 1 | Jan 16, 2026 | clinicaltrials |
| NCT06927570 | A Study of HS-20122 in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 1,050 | Hansoh BioMedical R&D CompanyINDUSTRY | 1 | Jan 16, 2026 | clinicaltrials |
| NCT06932952 | A Dose Escalation and Expansion Trial With BYON4228 Alone and in Combination in Patients With Advanced or Metastatic Solid Tumors | active not recruiting | Phase 1 | 7 | Byondis B.V.INDUSTRY | 3 | Jan 16, 2026 | clinicaltrials |
| NCT06973564 | JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration | recruiting | Phase 1 / Phase 2 | 294 | Jacobio Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Jan 16, 2026 | clinicaltrials |
| NCT07186452 | Evaluation of the Effect of Itraconazole on the Pharmacokinetics of HS-20093 in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 18 | Hansoh BioMedical R&D CompanyINDUSTRY | 1 | Jan 16, 2026 | clinicaltrials |
| NCT07231458 | A Study to Test a New Immunotherapy, ABX-001, Alone and in Combination With the Marketed Drug, Pembrolizumab, for the Treatment of Tumors Previously Treated With Other Therapies | recruiting | Phase 1 | 27 | Abalos Therapeutics GmbHINDUSTRY | 2 | Jan 16, 2026 | clinicaltrials |
| NCT07348042 | Study of RGL-270 Single Drug and Combined With Adebelimab in Patients in Patients at High Risk of Recurrence After Radical Treatment of Malignant Solid Tumors | recruiting | Phase 1 | 198 | Xian-Jun YuOTHER | 1 | Jan 16, 2026 | clinicaltrials |
| NCT05163041 | Study BT7480-100 in Patients With Advanced Malignancies Associated With Nectin-4 Expression | active not recruiting | Phase 1 / Phase 2 | 200 | BicycleTx LimitedINDUSTRY | 2 | Jan 15, 2026 | clinicaltrials |
| NCT07275242 | A Clinical Study of SHR-A1811(sc) Subcutaneous Injection in Patients With Solid Tumor | recruiting | Phase 1 | 107 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Jan 15, 2026 | clinicaltrials |
| NCT07339748 | A Clinical Study of ZL-85FA Tablets | not yet recruiting | Phase 1 / Phase 2 | 51 | Chengdu Zenitar Biomedical Technology Co., LtdINDUSTRY | 1 | Jan 15, 2026 | clinicaltrials |
| NCT06234423 | A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors | recruiting | Phase 1 | 263 | OnCusp Therapeutics, Inc.INDUSTRY | 2 | Jan 14, 2026 | clinicaltrials |
| NCT06334432 | Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 466 | Nuvation Bio Inc.INDUSTRY | 1 | Jan 14, 2026 | clinicaltrials |
| NCT07253116 | A Phase I/II Clinical Study of WJ22096 Tablets in Patients With Advanced Tumors | recruiting | Phase 1 / Phase 2 | 20 | Nanjing Jingao biomidical technology Co. Ltd.INDUSTRY | 1 | Jan 14, 2026 | clinicaltrials |
| NCT05156866 | First in Human Study of TORL-2-307-ADC in Participants With Advanced Cancer | active not recruiting | Phase 1 | 163 | TORL Biotherapeutics, LLCINDUSTRY | 2 | Jan 13, 2026 | clinicaltrials |
| NCT05651022 | Study of DECOY20 With or Without Tislelizumab in Patients With Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 120 | Indaptus Therapeutics, IncINDUSTRY | 1 | Jan 13, 2026 | clinicaltrials |
| NCT03829254 | A Safety, Pharmacokinetic and Clinical Activity Study of NUC-7738 in Patients With Advanced Solid Tumours and Lymphoma | recruiting | Phase 1 / Phase 2 | 135 | NuCana plcOTHER | 1 | Jan 12, 2026 | clinicaltrials |
| NCT05544552 | Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations(SURF301) | active not recruiting | Phase 1 / Phase 2 | 310 | Tyra Biosciences, IncINDUSTRY | 4 | Jan 12, 2026 | clinicaltrials |
| NCT07312903 | DPTX3186 in Wnt Pathway Activated Solid Tumors | recruiting | Phase 1 | 40 | Dewpoint TherapeuticsINDUSTRY | 1 | Jan 12, 2026 | clinicaltrials |
| NCT05490472 | JAB-2485 Activity in Adult Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 102 | Jacobio Pharmaceuticals Co., Ltd.INDUSTRY | 2 | Jan 9, 2026 | clinicaltrials |
| NCT06737731 | A Phase I/II Clinical Study of SHR-1681 for Injection in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 300 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Jan 9, 2026 | clinicaltrials |
| NCT06265727 | A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors | recruiting | Phase 1 / Phase 2 | 348 | Corbus Pharmaceuticals Inc.INDUSTRY | 7 | Jan 8, 2026 | clinicaltrials |
| NCT06631079 | Personalised Neoantigen-targeting Cancer Vaccine NECVAX-NEO1 in Anti-PD-1/PD-L1 Therapy in Patients With Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 20 | NEC Bio B.VINDUSTRY | 3 | Jan 8, 2026 | clinicaltrials |
| NCT06990464 | A Clinical Trial of SIBP-A19 Injection in the Treatment of Advanced Malignant Solid Tumor Patients | recruiting | Phase 1 | 156 | Shanghai Institute Of Biological ProductsINDUSTRY | 1 | Jan 8, 2026 | clinicaltrials |
| NCT07131202 | A Study of FL115 in Combination With a PD-1 Antibody in Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 130 | Suzhou Forlong Biotechnology Co., LtdINDUSTRY | 1 | Jan 8, 2026 | clinicaltrials |
| NCT07327294 | A Phase I/II Study to Evaluate XNW34017 in Patients With Advanced or Metastatic Solid Tumor | not yet recruiting | Phase 1 / Phase 2 | 150 | Evopoint Biosciences Inc.INDUSTRY | 1 | Jan 8, 2026 | clinicaltrials |
| NCT06235437 | Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ASD141 | recruiting | Phase 1 | 21 | Ascendo Biotechnology Co., Ltd.INDUSTRY | 1 | Jan 7, 2026 | clinicaltrials |
| NCT06298058 | A Clinical Trial of SIBP-A13 Injection in the Treatment of Advanced Malignant Solid Tumor Patients. | recruiting | Phase 1 | 144 | Shanghai Institute Of Biological ProductsINDUSTRY | 1 | Jan 7, 2026 | clinicaltrials |
| NCT06512116 | A Clinical Trial of SIBP-A17 Injection in the Treatment of Advanced Solid Tumor Patients. | recruiting | Phase 1 | 196 | Shanghai Institute Of Biological ProductsINDUSTRY | 1 | Jan 7, 2026 | clinicaltrials |
| NCT07232407 | A Study of Lutetium [177Lu] BL-ARC001 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors and Other Solid Tumors | recruiting | Phase 1 | 22 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jan 7, 2026 | clinicaltrials |
| NCT07274852 | A Study of Lutetium [177Lu]-BL-ARC001 in Patients With Locally Advanced or Metastatic Lung Cancer, Breast Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors | recruiting | Phase 1 | 22 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jan 6, 2026 | clinicaltrials |
| NCT05584800 | Study of ZGGS18 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 222 | Suzhou Zelgen Biopharmaceuticals Co.,LtdINDUSTRY | 1 | Jan 5, 2026 | clinicaltrials |
| NCT06938880 | Study of ZGGS18 in Combination With ZG005 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 60 | Suzhou Zelgen Biopharmaceuticals Co.,LtdINDUSTRY | 1 | Jan 5, 2026 | clinicaltrials |
| NCT07124117 | A Study Evaluating OBI-902 in Participants With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 147 | OBI Pharma, IncINDUSTRY | 2 | Jan 5, 2026 | clinicaltrials |
| NCT07252414 | GenSci143 in Participants With Advanced Solid Tumors | recruiting | Phase 1 | 180 | Changchun GeneScience Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jan 5, 2026 | clinicaltrials |
| NCT07310134 | Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of ZX-8177 in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 80 | Nanjing Zenshine PharmaceuticalsINDUSTRY | 1 | Jan 2, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Jan 28, 2026source: clinicaltrials